@article{4208233,
  abstract     = {{Introduction: With the introduction of biologic therapies, tremendous progress has been made in the treatment of rheumatoid arthritis (RA). However, up to 40% of patients do not respond to these treatments.
Areas covered: Several new treatment strategies are discussed, with brief overview of currently performed clinical trials. The development of molecules targeting cytokines other than TNF is discussed, as well as chemokine-directed drugs. Finally, the area of small molecular inhibitors is explored.
Expert opinion: Since RA is a life-long disease often evolving into disability, development of new treatment strategies remains crucial. Especially small molecules targeting JAK, Syk and PDE4 may provide novel therapeutic options.}},
  author       = {{Jacques, Peggy and Van den Bosch, Filip}},
  issn         = {{1472-8214}},
  journal      = {{EXPERT OPINION ON EMERGING DRUGS}},
  keywords     = {{rheumatoid arthritis,kinase inhibitors,PLACEBO-CONTROLLED TRIAL,NECROSIS-FACTOR-ALPHA,PROOF-OF-CONCEPT,PHASE-III TRIAL,INTERLEUKIN-1 RECEPTOR ANTAGONIST,MODIFYING ANTIRHEUMATIC DRUGS,RANDOMIZED CONTROLLED-TRIAL,CONTROLLED CLINICAL-TRIAL,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,RECEIVING CONCOMITANT METHOTREXATE,biological therapy,cytokines}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{231--244}},
  title        = {{Emerging therapies for rheumatoid arthritis}},
  url          = {{http://doi.org/10.1517/14728214.2013.807339}},
  volume       = {{18}},
  year         = {{2013}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: